Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety of the investigational study drug, selinexor
when given with docetaxel to patients who have been previously treated for advanced KRAS
mutant lung cancer.